Nautilus Biotechnology, Inc. reported results
SEC 8-KRead source ↗
Nautilus Biotechnology, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$0.8
Growth cash-flow model
Base case. Range ~$0.8–$0.9. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Nautilus Biotechnology, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 1 selling2 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
- Funds59 adding, 28 cuttingOf 22 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 16% in the quarter to 2026-09-30, the 4th beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 124% and a beta of 1.5 against the S&P 500.
- Short interest rising. Shares sold short rose 38% in a month to 9.0% of tradable shares.
Latest results
- Earnings per share
- -$0.12 against an average estimate of -$0.14: beat by 15.8%
- Share reaction
- +31.6% in the first session after the results on October 27, 2026, against +0.9% for the S&P 500
- Next report
- October 27, 2026
Price chart
- 1 day+0.9%
- 1 week-18.5%
- 1 month+20.2%
- This year+19.7%
- 1 year+27.3%
- 5 years-58.8%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.46
Growth
- Share count change
- +0.6%
Earnings
- Last results
- October 27, 2026
- Next results (est.)
- January 26, 2027
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Agreement
Nautilus Biotechnology, Inc. entered a material agreement; ended a material agreement
SEC 8-KRead source ↗ - Results
Nautilus Biotechnology, Inc. reported results
SEC 8-KRead source ↗
Valuation models
We value Nautilus Biotechnology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.8 ~$0.8–$0.9 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.1 ~$0.1–$0.3 | Left out: out of range vs price (0.06x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$0.8 ~$0.8–$0.9 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Nautilus Biotechnology, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.48 | −3% | $691330 | 0% |
| Next | −$0.48 | 0% | $6m | +709% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −4.0% on 90 days ago. In the last 30 days, 1 analyst raised Nautilus Biotechnology, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.51 | −$0.52 |
| 60 days ago | −$0.51 | −$0.52 |
| 30 days ago | −$0.51 | −$0.52 |
| 7 days ago | −$0.51 | −$0.52 |
| Now | −$0.48 | −$0.48 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Sept 2026 | −$0.14 | −$0.12 | +15.8% |
| Jun 2026 | −$0.14 | −$0.11 | +21.4% |
| Mar 2026 | −$0.14 | −$0.12 | +17.2% |
| Dec 2025 | −$0.14 | −$0.11 | +21.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 9.0% of tradable shares
- Days to cover
- 0.69 at average volume
- Short interest, 1 month
- +38% to October 15, 2026
- Held by institutions
- 43% of shares
- Held by insiders
- 32.0% of shares
- Employees
- 128 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| NAUT | −52% | −65% | +66% | −44% | +16% | +20% |
| Industry peers (median) | +5% | −51% | −3% | −13% | −7% | +15% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| NAUT | 33% | 42% | 58% | 33% | 50% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| NAUT | −80% | −71% | −48% | −48% | −69% | −78% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since August 7, 2020: 97% from February 8, 2021 to September 3, 2025. Getting back needed a 3410% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.85 – $3.95
- From 52-week high
- −40.9%
- vs 50-day average
- +44.2%
- vs 200-day average
- +10.2%
- Volatility (1 year)
- 124%
- Beta vs S&P 500
- 1.48
Share price after results
- Next day
- 5 up, 7 down typical move ±10.6%
- After a week
- 3 up, 8 down typical move ±13.5%
- After a month
- 5 up, 6 down typical move ±20.4%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| October 27, 2026 | +31.6% | +0.9% | — | — |
| July 28, 2026 | −37.3% | −1.3% | −40.7% | −43.6% |
| April 28, 2026 | −2.7% | −0.5% | +11.3% | +1.2% |
| February 26, 2026 | −16.3% | −1.0% | −15.6% | +20.4% |
| October 28, 2025 | +4.4% | +0.3% | +17.8% | +68.1% |
| July 31, 2025 | +0.5% | −2.0% | −2.0% | −10.5% |
| April 29, 2025 | +1.3% | +0.7% | −1.8% | +17.6% |
| February 27, 2025 | −9.1% | −0.1% | −20.3% | −37.9% |
| October 29, 2024 | −5.7% | −0.1% | −6.0% | −18.1% |
| July 30, 2024 | −1.1% | +1.1% | −16.4% | −4.4% |
| April 30, 2024 | +8.2% | −1.9% | +7.4% | +2.7% |
| February 28, 2024 | −8.5% | +0.2% | −8.8% | 0.0% |
Fundamentals
Dividends, buybacks and capital spending
- Diluted share count
- +0.6%
- year over year
Who owns it
Funds buying and selling- Reported value
- $93.7M
- Institutions reporting
- 92
- Shares held vs prior quarter
- ▼ 7.7%
- Positions opened / closed
- 31 / 16
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Perceptive Advisors LLC | $21.8M | 11.6M | 23.2% | ▼ 7.6% |
| A16Z Capital Management, L.L.C. | $16.9M | 9.1M | 18.1% | ▼ 48.7% |
| Cercano Management LLC | $13.4M | 7.2M | 14.3% | 0.0% |
| Blackrock, Inc. | $5M | 2.7M | 5.4% | ▲ 1331.9% |
| Vanguard Capital Management LLC | $4.8M | 2.5M | 5.1% | ▲ 0.2% |
| Comprehensive Financial Management LLC | $4.1M | 2.2M | 4.4% | 0.0% |
| Citadel Advisors LLC | $3.5M | 1.9M | 3.8% | New |
| Geode Capital Management, LLC | $2.4M | 1.3M | 2.5% | ▲ 109.7% |
| Acadian Asset Management LLC | $2M | 1.1M | 2.1% | ▲ 42.4% |
| Clearstead Advisors, LLC | $1.7M | 893K | 1.8% | ▼ 61.7% |
| Susquehanna International Group, LLP | $1.7M | 891K | 1.8% | New |
| Sentinel Trust Co Lba | $1.4M | 750K | 1.5% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Nautilus Biotechnology, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $71,198 2 trades by 2 insiders, last 12 months Insider sales History → $11.8M 2 trades by 1 insider · 0% under pre-set plans
Net ▼ $11.7M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Ah Equity Partners Bio Ii, L.L.C. 10% owner | June 2, 2026 | Sell | 384,026 | $2.35 | $902,461 |
| Ah Equity Partners Bio Ii, L.L.C. 10% owner | June 2, 2026 | Sell | 4,615,974 | $2.35 | $10.8M |
| Patel Sujal M CEO, President, and Secretary | March 4, 2026 | Buy | 25,000 | $2.61 | $65,238 |
| Suzuki Kentaro Chief Marketing Officer | November 6, 2025 | Buy | 4,000 | $1.49 | $5,960 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around January 26, 2027 estimated from the company's past filing pattern, not announced
- October 27, 2026
- July 28, 2026
- April 28, 2026
- February 26, 2026
- October 28, 2025
- July 31, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- S-3 S-3
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Nautilus Biotechnology, Inc. in brief
- What does Nautilus Biotechnology, Inc. do?
- Nautilus Biotechnology, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
- What is Nautilus Biotechnology, Inc.'s stock ticker?
- Nautilus Biotechnology, Inc. trades under the ticker NAUT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Nautilus Biotechnology, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Perceptive Advisors LLC, A16Z Capital Management, L.L.C. and Cercano Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Nautilus Biotechnology, Inc. stock?
- Over the last 12 months, Nautilus Biotechnology, Inc.'s directors and officers reported 2 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
- When is Nautilus Biotechnology, Inc.'s next earnings date?
- Around January 26, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Nautilus Biotechnology, Inc. announces its own schedule.
Follow research on Nautilus Biotechnology, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.